ArticlePublic health challenges2026
Real-World Pharmacological Management of Alcohol Dependence in a Nepalese Rehabilitation Center: Prospective Cohort Study.
Article in Public health challenges, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alcohol dependence syndrome (ADS) poses a significant public health issue in Nepal, necessitating effective pharmacological management. This study evaluated the real-world pharmacological management and short-term treatment outcomes of ADS patients in a rehabilitation center in Kathmandu, Nepal. Methods: A prospective cohort study was conducted among 96 adult ADS patients between November 2023 and April 2024. Alcohol consumption severity and withdrawal risk were assessed using validated tools (Alcohol Use Disorders Identification Test [AUDIT] and Prediction of Alcohol Withdrawal Severity Scale [PAWSS]). Treatment regimens, symptom profiles, and liver enzyme levels were documented. Statistical analysis included paired and independent Results: The cohort had a mean age of 37.8 years; 69% were male. At baseline, 96% were identified as problematic drinkers, and all were classified as high risk for withdrawal. Lorazepam (98.8%) and thiamine (97.9%) were the most commonly prescribed agents. A significant reduction in PAWSS scores was observed from admission to follow-up (7.06 ± 0.89 vs. 3.64 ± 0.94, Conclusion: Structured, evidence-informed pharmacological regimens were associated with improved clinical outcomes among ADS patients in this resource-limited setting. These findings support the integration of standardized ADS protocols in Nepalese rehabilitation centers. Multicenter studies with long-term follow-up are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.